Company intelligence / Profile preview

Aperiomics

Sterling, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Aperiomics developed pathogen detection capabilities using deep shotgun metagenomic sequencing and bioinformatics to identify infectious diseases. The company launched a COVID-19 test (Xplore-COVID-19) in March 2020 with PCR-based detection, capable of processing up to 1000 tests per week with 48-72 hour turnaround time at $250 per test[1]. The company was known as the only firm able to identify every known bacterium, virus, fungus, and parasite through its Xplore-PATHO test[1].

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic test
Industry: Molecular Diagnostics

Partnerships

Integrated DNA Technologies (IDT)Zymo Research

Beyond the preview

Go deeper on Aperiomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aperiomics.

Explore the full profile